drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous T cells engineered to express a chimeric antigen receptor targeting CD30 for MHC-independent activation and killing of CD30-positive Hodgkin and T-cell lymphomas.
nci_thesaurus_concept_id
C201513
nci_thesaurus_preferred_term
Anti-CD37-CAR-expressing T-lymphocytes
nci_thesaurus_definition
A preparation of T-lymphocytes that express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD30.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express a chimeric antigen receptor specific for CD30, enabling MHC-independent recognition of CD30-positive tumor cells. Upon binding CD30, CAR signaling activates the T cells, inducing proliferation, cytokine release, and cytotoxic killing via perforin/granzyme-mediated lysis of CD30-expressing Hodgkin and T-cell lymphoma cells.
drug_name
Anti-CD30 CAR T cells
nct_id_drug_ref
NCT06756321